Global Diabetic Gastroparesis 麻豆原创 Research Report 2023

Publication ID:

PB504241725

Publication Date:

May 3, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Diabetes type 1 and type 2 are one of the most common chronic diseases prevalent in the world, affecting millions of people. One of the disorders associated with diabetes type 1 and type 2 is gastroparesis, which is characterized by the delayed emptying of the stomach. One of the major causes of gastroparesis is damage to the vagus nerve, reducing the mobility of the stomach contents. Diabetic neuropathy affects the vagus nerve, in cases where the blood glucose levels remain high over a longer duration. Diabetes gastroparesis is usually diagnosed with the help of imaging techniques such as ultrasound and x-ray, which is accompanied by the intake of radio isotopic meals containing barium, or using hematological / blood tests, and endoscopic techniques. There has been a marked increase in the prevalence of diabetes, especially in the developing countries, including China, India, Brazil, and some other Asian countries, leading to increasing incidence of diabetic neuropathy and consequent rise in diabetes gastroparesis around the world.
Highlights
The global Diabetic Gastroparesis market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Diabetic Gastroparesis is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Diabetic Gastroparesis is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Diabetic Gastroparesis in Hospital Pharmacies is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Diabetic Gastroparesis include Medtronic, Sumitomo Dainippon Pharma, Abbott Laboratories, Boston Scientific Corporation, C. R. Bard, Inc, Janssen Global Services, LLC, Alfasigma SpA, Evoke Pharma and Cadila Pharmaceuticals, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Diabetic Gastroparesis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetic Gastroparesis.
The Diabetic Gastroparesis market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Diabetic Gastroparesis market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diabetic Gastroparesis companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Medtronic
Sumitomo Dainippon Pharma
Abbott Laboratories
Boston Scientific Corporation
C. R. Bard, Inc
Janssen Global Services, LLC
Alfasigma SpA
Evoke Pharma
Cadila Pharmaceuticals
Sanofi
Teva Pharmaceutical Industries Ltd
Pfizer
Vanda Pharmaceuticals
Allergan
Segment by Type
Drugs
Surgical Treatment Products
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Diabetic Gastroparesis companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Diabetic Gastroparesis 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Drugs
1.2.3 Surgical Treatment Products
1.3 麻豆原创 by Application
1.3.1 Global Diabetic Gastroparesis 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Gastroparesis 麻豆原创 Perspective (2018-2029)
2.2 Diabetic Gastroparesis Growth Trends by Region
2.2.1 Global Diabetic Gastroparesis 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Diabetic Gastroparesis Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Diabetic Gastroparesis Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Diabetic Gastroparesis 麻豆原创 Dynamics
2.3.1 Diabetic Gastroparesis Industry Trends
2.3.2 Diabetic Gastroparesis 麻豆原创 Drivers
2.3.3 Diabetic Gastroparesis 麻豆原创 Challenges
2.3.4 Diabetic Gastroparesis 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Gastroparesis Players by Revenue
3.1.1 Global Top Diabetic Gastroparesis Players by Revenue (2018-2023)
3.1.2 Global Diabetic Gastroparesis Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Diabetic Gastroparesis 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Diabetic Gastroparesis Revenue
3.4 Global Diabetic Gastroparesis 麻豆原创 Concentration Ratio
3.4.1 Global Diabetic Gastroparesis 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Gastroparesis Revenue in 2022
3.5 Diabetic Gastroparesis Key Players Head office and Area Served
3.6 Key Players Diabetic Gastroparesis Product Solution and Service
3.7 Date of Enter into Diabetic Gastroparesis 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Diabetic Gastroparesis Breakdown Data by Type
4.1 Global Diabetic Gastroparesis Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Diabetic Gastroparesis Forecasted 麻豆原创 Size by Type (2024-2029)
5 Diabetic Gastroparesis Breakdown Data by Application
5.1 Global Diabetic Gastroparesis Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Diabetic Gastroparesis Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Diabetic Gastroparesis 麻豆原创 Size (2018-2029)
6.2 North America Diabetic Gastroparesis 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Diabetic Gastroparesis 麻豆原创 Size by Country (2018-2023)
6.4 North America Diabetic Gastroparesis 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Diabetic Gastroparesis 麻豆原创 Size (2018-2029)
7.2 Europe Diabetic Gastroparesis 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Diabetic Gastroparesis 麻豆原创 Size by Country (2018-2023)
7.4 Europe Diabetic Gastroparesis 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Diabetic Gastroparesis 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Diabetic Gastroparesis 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Diabetic Gastroparesis 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Diabetic Gastroparesis 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Diabetic Gastroparesis 麻豆原创 Size (2018-2029)
9.2 Latin America Diabetic Gastroparesis 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Diabetic Gastroparesis 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Diabetic Gastroparesis 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Diabetic Gastroparesis 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Diabetic Gastroparesis 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Diabetic Gastroparesis 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Diabetic Gastroparesis 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Medtronic
11.1.1 Medtronic Company Detail
11.1.2 Medtronic Business Overview
11.1.3 Medtronic Diabetic Gastroparesis Introduction
11.1.4 Medtronic Revenue in Diabetic Gastroparesis Business (2018-2023)
11.1.5 Medtronic Recent Development
11.2 Sumitomo Dainippon Pharma
11.2.1 Sumitomo Dainippon Pharma Company Detail
11.2.2 Sumitomo Dainippon Pharma Business Overview
11.2.3 Sumitomo Dainippon Pharma Diabetic Gastroparesis Introduction
11.2.4 Sumitomo Dainippon Pharma Revenue in Diabetic Gastroparesis Business (2018-2023)
11.2.5 Sumitomo Dainippon Pharma Recent Development
11.3 Abbott Laboratories
11.3.1 Abbott Laboratories Company Detail
11.3.2 Abbott Laboratories Business Overview
11.3.3 Abbott Laboratories Diabetic Gastroparesis Introduction
11.3.4 Abbott Laboratories Revenue in Diabetic Gastroparesis Business (2018-2023)
11.3.5 Abbott Laboratories Recent Development
11.4 Boston Scientific Corporation
11.4.1 Boston Scientific Corporation Company Detail
11.4.2 Boston Scientific Corporation Business Overview
11.4.3 Boston Scientific Corporation Diabetic Gastroparesis Introduction
11.4.4 Boston Scientific Corporation Revenue in Diabetic Gastroparesis Business (2018-2023)
11.4.5 Boston Scientific Corporation Recent Development
11.5 C. R. Bard, Inc
11.5.1 C. R. Bard, Inc Company Detail
11.5.2 C. R. Bard, Inc Business Overview
11.5.3 C. R. Bard, Inc Diabetic Gastroparesis Introduction
11.5.4 C. R. Bard, Inc Revenue in Diabetic Gastroparesis Business (2018-2023)
11.5.5 C. R. Bard, Inc Recent Development
11.6 Janssen Global Services, LLC
11.6.1 Janssen Global Services, LLC Company Detail
11.6.2 Janssen Global Services, LLC Business Overview
11.6.3 Janssen Global Services, LLC Diabetic Gastroparesis Introduction
11.6.4 Janssen Global Services, LLC Revenue in Diabetic Gastroparesis Business (2018-2023)
11.6.5 Janssen Global Services, LLC Recent Development
11.7 Alfasigma SpA
11.7.1 Alfasigma SpA Company Detail
11.7.2 Alfasigma SpA Business Overview
11.7.3 Alfasigma SpA Diabetic Gastroparesis Introduction
11.7.4 Alfasigma SpA Revenue in Diabetic Gastroparesis Business (2018-2023)
11.7.5 Alfasigma SpA Recent Development
11.8 Evoke Pharma
11.8.1 Evoke Pharma Company Detail
11.8.2 Evoke Pharma Business Overview
11.8.3 Evoke Pharma Diabetic Gastroparesis Introduction
11.8.4 Evoke Pharma Revenue in Diabetic Gastroparesis Business (2018-2023)
11.8.5 Evoke Pharma Recent Development
11.9 Cadila Pharmaceuticals
11.9.1 Cadila Pharmaceuticals Company Detail
11.9.2 Cadila Pharmaceuticals Business Overview
11.9.3 Cadila Pharmaceuticals Diabetic Gastroparesis Introduction
11.9.4 Cadila Pharmaceuticals Revenue in Diabetic Gastroparesis Business (2018-2023)
11.9.5 Cadila Pharmaceuticals Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Diabetic Gastroparesis Introduction
11.10.4 Sanofi Revenue in Diabetic Gastroparesis Business (2018-2023)
11.10.5 Sanofi Recent Development
11.11 Teva Pharmaceutical Industries Ltd
11.11.1 Teva Pharmaceutical Industries Ltd Company Detail
11.11.2 Teva Pharmaceutical Industries Ltd Business Overview
11.11.3 Teva Pharmaceutical Industries Ltd Diabetic Gastroparesis Introduction
11.11.4 Teva Pharmaceutical Industries Ltd Revenue in Diabetic Gastroparesis Business (2018-2023)
11.11.5 Teva Pharmaceutical Industries Ltd Recent Development
11.12 Pfizer
11.12.1 Pfizer Company Detail
11.12.2 Pfizer Business Overview
11.12.3 Pfizer Diabetic Gastroparesis Introduction
11.12.4 Pfizer Revenue in Diabetic Gastroparesis Business (2018-2023)
11.12.5 Pfizer Recent Development
11.13 Vanda Pharmaceuticals
11.13.1 Vanda Pharmaceuticals Company Detail
11.13.2 Vanda Pharmaceuticals Business Overview
11.13.3 Vanda Pharmaceuticals Diabetic Gastroparesis Introduction
11.13.4 Vanda Pharmaceuticals Revenue in Diabetic Gastroparesis Business (2018-2023)
11.13.5 Vanda Pharmaceuticals Recent Development
11.14 Allergan
11.14.1 Allergan Company Detail
11.14.2 Allergan Business Overview
11.14.3 Allergan Diabetic Gastroparesis Introduction
11.14.4 Allergan Revenue in Diabetic Gastroparesis Business (2018-2023)
11.14.5 Allergan Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Medtronic
Sumitomo Dainippon Pharma
Abbott Laboratories
Boston Scientific Corporation
C. R. Bard, Inc
Janssen Global Services, LLC
Alfasigma SpA
Evoke Pharma
Cadila Pharmaceuticals
Sanofi
Teva Pharmaceutical Industries Ltd
Pfizer
Vanda Pharmaceuticals
Allergan

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.